Logo for ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Investor Relations Material

Latest events

Logo for ACADIA Pharmaceuticals Inc

Q1 2024

ACADIA Pharmaceuticals
Logo for ACADIA Pharmaceuticals

Q1 2024

8 May, 2024
Logo for ACADIA Pharmaceuticals

Q4 2023

27 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from ACADIA Pharmaceuticals Inc

Access all reports
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).